Published on September 19, 2023 at 18:21 Updated on September 19, 2023 at 18:25
The biggest rise of the day within the SRD, Phaxiam Therapeutics soared 58%, to 4.90 euros. The biotechnology company born from the merger between Pherecydes and Erytech announced this Tuesday the expansion of its portfolio of phages, natural viruses that kill bacteria, to a new resistant and aggressive bacterial target, Klebsiella pneumoniae (or K. pneumoniae), which mainly infects people immunocompromised. .
It is estimated that, in Western countries, between 3 and 5% of pneumonias are related to infection caused by K. pneumoniae, the company said in its press release. Globally, the target bacteria is responsible for 11.8% of hospital-acquired pneumonia. The incidence of resistance to K. pneumoniae is estimated at between 90,000 and 100,000 patients in the United States and five major European countries, particularly through urinary and lung infections.
An announcement that comes the day after the grouping of shares by 10. The new shares have been assigned another ISIN code: FR001400K4B1. Therefore, the number of titles falls from about 60.75 million to 6.07 million.
What stocks to buy?
Making the best investments requires detailed knowledge of the markets, their mechanisms, the economy and involves delving into the heart of the strategy of each listed company. Investir’s editorial team does it for you and offers its subscribers advice on more than 800 stocks. Benefit from their buy, speculative buy, spread or sell recommendations by subscribing to Investir.
I discover the offers
